BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31689521)

  • 1. The association between nonsteroidal anti-inflammatory drugs and skin cancer: Different responses in American and European populations.
    Ma Y; Yu P; Lin S; Li Q; Fang Z; Huang Z
    Pharmacol Res; 2020 Feb; 152():104499. PubMed ID: 31689521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.
    Jaturapatporn D; Isaac MG; McCleery J; Tabet N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006378. PubMed ID: 22336816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study.
    Johannesdottir SA; Chang ET; Mehnert F; Schmidt M; Olesen AB; Sørensen HT
    Cancer; 2012 Oct; 118(19):4768-76. PubMed ID: 22644960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer.
    Reinau D; Surber C; Jick SS; Meier CR
    Int J Cancer; 2015 Jul; 137(1):144-53. PubMed ID: 25418602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin and nonsteroidal anti-inflammatory drug use and keratinocyte cancers: a large population-based cohort study of skin cancer in Australia.
    Pandeya N; Olsen CM; Thompson BS; Dusingize JC; Neale RE; Green AC; Whiteman DC;
    Br J Dermatol; 2019 Oct; 181(4):749-760. PubMed ID: 30920641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies.
    Ungprasert P; Cheungpasitporn W; Crowson CS; Matteson EL
    Eur J Intern Med; 2015 May; 26(4):285-91. PubMed ID: 25862494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancer: evidence from meta-analysis.
    Zhang B; Liang X; Ye L; Wang Y
    PLoS One; 2014; 9(5):e96887. PubMed ID: 24828489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS; Shapiro D; Sperling RS; Barr E; Yu Q
    Am J Cardiol; 2002 Jan; 89(2):204-9. PubMed ID: 11792343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
    Ungprasert P; Matteson EL; Thongprayoon C
    Stroke; 2016 Feb; 47(2):356-64. PubMed ID: 26670086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
    Ziesenitz VC; Welzel T; van Dyk M; Saur P; Gorenflo M; van den Anker JN
    Paediatr Drugs; 2022 Nov; 24(6):603-655. PubMed ID: 36053397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials.
    Pavelka K
    Curr Med Res Opin; 2012 Jan; 28(1):163-78. PubMed ID: 22168216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).
    Castellsague J; Riera-Guardia N; Calingaert B; Varas-Lorenzo C; Fourrier-Reglat A; Nicotra F; Sturkenboom M; Perez-Gutthann S;
    Drug Saf; 2012 Dec; 35(12):1127-46. PubMed ID: 23137151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
    Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
    Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.